# Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

> **NCT03609840** · — · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 25 (actual)

## Conditions studied

- Hematologic Malignancies
- Nonmalignant Diseases
- Immune Deficiency
- Hemoglobinopathies
- Genetic Inborn Errors of Metabolism
- Fanconi Anemia
- Thalassemia
- Sickle Cell Disease

## Interventions

- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT03609840
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-24
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609840, "Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03609840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*